Due to the use of HepG2.215 and HepAD38 cells that integrated with the HBV genome in this study, rather than adding HBV particles to the cell culture medium to carry out infection experiments, we are currently unable to reveal the specific sites and time points at which ABHD16A and IFITM1 exert antiviral effects. This evidence concerns the gene IFITM1 and infection.